摘要
采用组织芯片技术结合免疫组织化学技术检测各类型食管癌(鳞状细胞癌、腺癌、小细胞癌)以及食管胃交界癌、胃癌中细胞周期素依赖性激酶16(cyclin dependent kinase 16,CDK16)的表达情况.使用数学统计分析软件研究CDK16蛋白的表达与食管鳞癌临床病理特征之间的关系.结果显示,CDK16在不同类型食管癌中的表达存在差异.CDK16在食管鳞癌中呈强阳性表达,且表达强度与肿瘤的分化程度负相关.CDK16在食管鳞癌细胞中表达部位的变化与肿瘤的恶性程度密切相关.CDK16的表达与食管鳞癌患者的性别、年龄、肿瘤部位、肿瘤最大径及肿瘤的病理形态均没有显著相关性(P>0.05),而与肿瘤的病理分级、淋巴结转移及TNM临床分期有显著相关性(P<0.05).以上结果表明,CDK16在食管癌中的表达具有组织学特异性.CDK16在食管鳞癌的发病过程中发挥着重要的作用,而检测CDK16的表达有助于食管鳞癌的临床诊断.
The expression of CDK16(cyclin dependent kinase 16)in various types of esophageal cancers(squamous cell carcinoma,adenocarcinoma,small cell carcinoma),esophagogastric junction cancers and gastric cancers was detected by tissue microarray technique combined with immunohistochemistry.The relationship between the expression of CDK16 and the clinicopathological features of esophageal squamous cell carcinoma was studied by using mathematical statistical analysis software.The results indicate there are differences in the expression of CDK16 in different types of esophageal cancers.Expression of CDK16 is strongly positive in the esophageal squamous cell carcinoma,and the intensity of the expression is negatively correlated with the degree of differentiation of the tumor.The changes in the expression site of CDK16 in the cell are closely related to the malignancy of the tumor.The expressions of CDK16 in esophageal squamous cell carcinoma with gender and age of patients,tumor location,tumor maximum diameter and pathological morphology of tumor show no significant difference(P>0.05),and the tumor pathological grading,lymph node metastasis and TNM clinical stage have significant difference(P <0.05).The expression of CDK16 in esophageal carcinoma has histological specificity.CDK16 plays an important role in the pathogenesis of esophageal squamous cell carcinoma,and detection of the expression of CDK16 is helpful to the clinical diagnosis of esophageal squamous cell carcinoma.
引文
[1]CHUNG L K,PELARGOS P E,CHAN A M,et al.Tissue microarray analysis for epithelial membrane protein-2as a novel biomarker for gliomas[J].Brain Tumor Pathology,2018,35(1):1-9.
[2]SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2018[J].CA-a Cancer Journal for Clinicians,2018,68(1):7-30.
[3]RUSTGI A,EL-SERAG H B.Esophageal carcinoma[J].New England Journal of Medicine,2014,371(26):2499-2509.
[4]JAIN S,DHINGRA S.Pathology of esophageal cancer and Barrett's esophagus[J].Annals of Cardiothoracic Surgery,2017,6(2):99-109.
[5]LIN Y,TOTSUKA Y,SHAN B,et al.Esophageal cancer in high-risk areas of China:Research progress and challenges[J].Annals of Epidemiology,2017,27(3):215-221.
[6]BOEYNAEMS S,TOMPA P,VAN DEN B L,et al.Phasing in on the cell cycle[J].Cell Division,2018,13(1):1-8.
[7]GERARD C,GOLDBETER A.Dynamics of the mammalian cell cycle in physiological and pathological conditions[J].Wiley Interdisciplinary Reviews-Systems Biology and Medicine,2016,8(2):140-156.
[8]MALUMBRES M.Cyclin-dependent kinases[J].Genome Biology,2014,15(6):122-132.
[9]GITIG D M,KOFF A.Cdk pathway:Cyclin-dependent kinases and cyclin-dependent kinase inhibitors[J].Molecular Biotechnology,2001,19(2):179-188.
[10]SANTO L,SIU K T,RAJE N.Targeting cyclin-dependent kinases and cell cycle progression in human cancers[J].Seminars in Oncology,2015,42(6):788-800.
[11]SHAPIRO G I.Cyclin-dependent kinase pathways as targets for cancer treatment[J].Journal of Clinical Oncology,2006,24(11):1770-1783.
[12]ZHANG J,ZHU J,YANG L,et al.Interaction with CCNH/CDK7facilitates CtBP2promoting esophageal squamous cell carcinoma(ESCC)metastasis via upregulating epithelial-mesenchymal transition(EMT)progression[J].Tumor Biology,2015,36(9):6701-6714.
[13]BABA Y,WATANABE M,MURATA A,et al.LINE-1hypomethylation,DNA copy number alterations,and CDK6amplification in esophageal squamous cell carcinoma[J].Clinical Cancer Research,2014,20(5):1114-1124.
[14]MIYAGAKI H,YAMASAKI M,MIYATA H,et al.Overexpression of PFTK1predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma[J].British Journal of Cancer,2012,106(5):947-954.
[15]ZHOU Q,YU Y N.Upregulated CDK16expression in serous epithelial ovarian cancer cells[J].Medical Science Monitor,2015,21(1):3409-3414.
[16]TIAN F,WEI H,TIAN H,et al.MiR-33ais downregulated in melanoma cells and modulates cell proliferation by targeting PCTAIRE1[J].Oncology Letters,2016,11(4):2741-2746.
[17]YANAGI T,KRAJEWSKA M,MATSUZAWA S,et al.PCTAIRE1phosphorylates p27and regulates mitosis in cancer cells[J].Cancer Research,2014,74(20):5795-5807.
[18]MEYERSON M,ENDERS G H,WU C L,et al.A family of human cdc2-related protein kinases[J].EMBO Journal,1992,11(8):2909-2917.
[19]ZI Z,ZHANG Z,LI Q,et al.CCNYL1,but not CCNY,cooperates with CDK16to regulate spermatogenesis in mouse[J].PLoS Genetics,2015,11(8):e1005485.
[20]SHIMIZU K,UEMATSU A,IMAI Y,et al.Pctaire1/Cdk16promotes skeletal myogenesis by inducing myoblast migration and fusion[J].FEBS Letters,2014,588(17):3030-3037.
[21]PAULINA C′,ZAIRA L,FABIANA S,et al.RNA interference screening identifies a novel role for PCTK1/CDK16in medulloblastoma with c-Myc amplification[J].Oncotarget,2015,6(1):116-129.
[22]TERUKI Y,RANXIN S,PEDRO A,et al.PCTAIRE1-knockdown sensitizes cancer cells to TNF family cytokines[J].PLoS One,2015,10(3):1-19.